• Paul M Matthews, Frederico Roncaroli, Adam Waldman, Maria Pia Sormani, Nicola De Stefano, Gavin Giovannoni, and Richard Reynolds.
• Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK.
• Pract Neurol. 2016 Aug 1; 16 (4): 279-87.

AbstractThe variability in the severity and clinical course of multiple sclerosis (MS) has as its basis an extreme heterogeneity in the location, nature and extent of pathology in the brain and spinal cord. Understanding the underlying neuropathology and associated pathogenetic mechanisms of the disease helps to communicate the rationale for treatment and disease monitoring to patients. Neuroimaging is an important tool for this: it allows clinicians to relate neuropathological changes to clinical presentations and to monitor the course of their disease. Here, we review MS neuropathology and its imaging correlates to provide a practical guide for using MRI to assess disease severity and treatment responses. This provides a foundation for optimal management of patients based on the principle that they show 'no evidence of disease activity'. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

11 keywords...

hide…